CML cell lines, derived from patients and driven by BCR::ABL1 activity, accurately recapitulate in vivo leukemic cells, and the resistance mechanisms observed in patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.